Lumos Pharma, Inc. (LUMO)
NASDAQ: LUMO · Real-Time Price · USD
4.370
-0.080 (-1.80%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases.

Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.

The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease.

Lumos Pharma, Inc. is headquartered in Austin, Texas.

Lumos Pharma, Inc.
Lumos Pharma logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 33
CEO Richard Hawkins

Contact Details

Address:
4200 Marathon Boulevard, Suite 200
Austin, Texas 78756
United States
Phone 512 215 2630
Website lumos-pharma.com

Stock Details

Ticker Symbol LUMO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001126234
CUSIP Number 55028X109
ISIN Number US55028X1090
Employer ID 42-1491350
SIC Code 2834

Key Executives

Name Position
Richard J. Hawkins Founder, Chief Executive Officer and Chairman
Dr. John C. McKew Ph.D. Chief Scientific Officer and President
Lori D. Lawley CPA Chief Financial Officer and Principal Accounting Officer
Lisa Wells Miller Senior Director of Investor Relations
Bradley J. Powers J.D. Chief Compliance Officer and General Counsel
Aaron Schuchart B.B.A., CPA, M.B.A. Chief Business Officer
Dr. Pisit Pitukcheewanont FAAP, M.D. Chief Medical Officer
Alpa Parikh Senior Vice President of CMC and Supply Management
Eddie L. Varnado M.B.A. Corporate Controller

Latest SEC Filings

Date Type Title
Oct 25, 2024 SCHEDULE 13G/A Filing
Oct 23, 2024 SC14D9C Filing
Oct 23, 2024 8-K Current Report
Aug 2, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
Jun 5, 2024 8-K Current Report
May 15, 2024 10-Q Quarterly Report
May 15, 2024 8-K Current Report
Apr 22, 2024 10-K/A [Amend] Annual report
Apr 18, 2024 8-K Current Report